NCT03292848View on ClinicalTrials.gov

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

May 21, 2018

Study Completion Date

May 21, 2018

Conditions

ADHDAutismBipolar I DisorderConduct DisorderOppositional Defiant Disorder

Interventions

DRUG

Brexpiprazole

Tablet

Trial Locations (9)

28211

New Hope Clinical Research, Charlotte

72211

Woodland International Research Group, Little Rock

72758

Woodland Research Northwest, LLC, Rogers

73103

IPS Research Company, Oklahoma City

73116

Cutting Edge Research Group, Oklahoma City

78229

Clinical Trials of Texas, Inc., San Antonio

78249

Road Runner Research Ltd., San Antonio

84058

Aspen Clinical Research, Orem

90807

Alliance for Wellness dba Alliance for Research, Long Beach

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders | Biotech Hunter | Biotech Hunter